Structural heart disease refers to cardiac defects that are congenital in nature and can also be acquired through wear & tear of heart valves or chambers of the heart. Rapid advancements in the medical field have replaced the open heart surgical procedures with non-surgical minimally invasive procedures such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR).
Currently, the global structural heart devices market is growing at a steady pace owing to the rise in incidence of structural heart diseases (aortic stenosis and mitral regurgitation) and development of minimally invasive technologies. According to the Micro Interventional Devices, Inc., about 60 million people in the U.S. suffer from structural heart defects. Moreover, as per the National Heart, Lung and Blood Institute, more than 35,000 babies are born with congenital heart defects in the U.S. These estimates are expected to boost the demand for structural heart devices during the forecast period. High cost of surgeries, risks associated with these surgeries, and lack of skilled cardiologists restrict this market growth. However, emerging markets (India and China) and increase in demand for structural heart procedures are expected to provide lucrative opportunities to the key players. The structural heart devices market is projected to reach $12,076 million by 2022 from $6,006 million in 2015, growing at a CAGR of 10.5% from 2016 to 2022.
The report segments the market based on product type, indication, age group, and geography. Based on product type, the market is bifurcated into repair devices (annuloplasty rings, heart valve balloons, and occluders) and replacement valves (mechanical and tissue heart valves]. Based on indication, it is divided into atrial septal defect (ASD), patent foramen ovale (PFO), and ventricular septal defect (VSD), aortic valve stenosis, and others. In terms of age group, it is further categorized as pediatrics and adults. The pediatrics’ age group is segmented into newborns (0–5 months), infants (6 months to 12 months), toddlers (1–2 years), preschoolers (3–5 years), school-aged children (6–12 years), and adolescents (13–18 years). The adult age group market is further segmented into young adults (19–24 years), adulthood (25–39 years), middle-aged (40–59 years), older people/old age (60–84 years), and very old (85+ years). Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
1.1. Report Description
1.1.1. Key Benefits For Stakeholders
1.1.2. Key Market Segments
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
1.2.3. Analyst Tools And Models
Chapter: 2 Executive Summary
2.1. CXO Perspective
Chapter: 3 Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
18.104.22.168. Competitive Intelligence Of Companies And Their Strategies
3.2.3. Market Share Analysis, 2015
3.3. Market Dynamics
22.214.171.124. Rise In Number Of Patients Suffering From Structural Heart Diseases
126.96.36.199. Increase In Risk Of Cardiovascular Diseases Owing To Growing Globalization And Industrialization
188.8.131.52. Technological Advancements In Heart Repair And Replacement Devices
184.108.40.206. Growth In Demand For Minimally Invasive Procedures
220.127.116.11. High Cost And Risk Associated With The Treatment Procedures
18.104.22.168. Stringent Approval Process For Structural Heart Devices
22.214.171.124. Lucrative Opportunities In Emerging Economies
3.4. Mitraclip Mitral Valve Repair System
3.5. Government Regulations
3.5.2. Health Canada
3.5.3. Ce Mark
3.5.4. Ministry Of Health, Labour And Welfare (Mhlw)
3.5.5. Therapeutic Goods Administration (Tga)
3.6. Reimbursement Scenario
3.7. Clinical Trials
Chapter: 4 Structural Heart Devices Market, By Product
4.1.1. Market Size And Forecast
4.2. Structural Heart Repair Devices
4.2.1. Key Market Trends
4.2.2. Key Growth Factors And Opportunities
4.2.3. Market Size And Forecast
126.96.36.199. Market Size And Forecast
4.2.5. Annuloplasty Rings
188.8.131.52. Market Size And Forecast
4.2.6. Heart Valve Balloons
184.108.40.206. Market Size And Forecast
4.3. Structural Heart Replacement Devices
4.3.1. Key Market Trends
4.3.2. Key Growth Factors And Opportunities
4.3.3. Market Size And Forecast
4.3.4. Mechanical Valves
4.3.5. Market Size And Forecast
4.3.6. Tissue Valves
4.3.7. Market Size And Forecast
Chapter: 5 Structural Heart Devices Market, By Age Group
5.1.1. Market Size And Forecast
5.2.5. School-Aged Children
5.2.7. Market Size And Forecast
5.3.1. Young Adults
5.3.3. Middle-Aged Persons
5.3.4. Older People/Old Age
5.3.5. Very Old
5.3.6. Market Size And Forecast
Chapter: 6 Structural Heart Devices Market, By Indication
6.1.1. Market Size And Forecast
6.2. Atrial Septal Defect
6.2.1. Market Size And Forecast
6.3. Patent Foramen Ovale
6.3.1. Market Size And Forecast
6.4. Ventricular Septal Defect
6.4.1. Market Size And Forecast
6.5. Aortic Valve Stenosis
6.5.1. Market Size And Forecast
6.6. Other Indications
6.6.1. Market Size And Forecast
Chapter: 7 Structural Heart Devices Market, By Geography
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends
7.2.2. Key Growth Factors And Opportunities
7.2.3. Market Size And Forecast
7.2.4. U.S. Market Size And Forecast
7.2.5. Canada Market Size And Forecast
7.2.6. Mexico Market Size And Forecast
7.3.1. Key Market Trends
7.3.2. Key Growth Factors And Opportunities
7.3.3. Market Size And Forecast
7.3.4. Germany Market Size And Forecast
7.3.5. France Market Size And Forecast
7.3.6. Uk Market Size And Forecast
7.3.7. Italy Market Size And Forecast
7.3.8. Spain Market Size And Forecast
7.3.9. Rest Of Europe Market Size And Forecast
7.4.1. Key Market Trends
7.4.2. Key Growth Factors And Opportunities
7.4.3. Market Size And Forecast
7.4.4. Japan Market Size And Forecast
7.4.5. China Market Size And Forecast
7.4.6. India Market Size And Forecast
7.4.7. Australia Market Size And Forecast
7.4.8. Malaysia Market Size And Forecast
7.4.9. Rest Of Asia-Pacific Market Size And Forecast
7.5.1. Key Market Trends
7.5.2. Key Growth Factors And Opportunities
7.5.3. Market Size And Forecast
7.5.4. Brazil Market Size And Forecast
7.5.5. South Africa Market Size And Forecast
7.5.6. South Arabia Market Size And Forecast
7.5.7. Rest Of Lamea Market Size And Forecast
Chapter: 8 Company Profiles
8.1. St. Jude Medical, Inc.
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Business Performance
8.1.5. Key Strategic Moves And Developments, 2012-2016
8.2. Braile Biomedica
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Product Categories
8.3. Boston Scientific Corporation
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Business Performance
8.3.5. Key Strategic Moves And Developments, 2011-2016
8.4. Cryolife, Inc.
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Business Performance
8.4.5. Key Strategic Moves And Developments, 2011-2016
8.5. Edwards Lifesciences Corporation
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Business Performance
8.5.5. Key Strategic Moves And Developments, 2014-2016
8.6. Jenavalve Technology, Inc.
8.6.2. Company Snapshot
8.6.3. Key Strategic Moves And Developments, 2011-2013
8.7. Livanova Plc
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Business Performance
8.7.5. Key Strategic Moves And Developments, 2016
8.8. Medical Technology Est.
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.9. Medtronic Plc
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Business Performance
8.9.5. Key Strategic Moves And Developments, 2015-2016
8.10. Micro Interventional Devices, Inc.
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
Rise in incidence of aortic stenosis, introduction of technologically advanced products (such as the Trifecta valve with Glide Technology), and increase in awareness about the benefits and availability of structural heart devices worldwide are major factors that drive the market growth. In addition, increase in number of application areas for repair and replacement devices coupled with its rise in adoption of annuloplasty rings and tissue valves is expected to further fuel this growth. However, stringent approval process and high cost of surgeries restrict the market growth.
Tissue heart valves is expected to maintain its dominant position throughout the analysis period, due to its significant property of low requirement of anticoagulants, which reduces incidence of bleeding and thereby lowers the usage of anticoagulant by the patient.
The occluders segment accounted for two-fifths of the overall structural heart repair devices market in 2015, owing to its benefits in the treatment of congenital heart diseases and high adoption rate. In addition, annuloplasty ring is projected to register the highest CAGR of 13.3% during the forecast period.
Key Findings of Structural Heart Devices Market:
Annuloplasty ring is projected to grow at the highest growth rate during the analysis period.
North America dominated the global structural heart devices market, accounting for one-third of the overall market in 2015, owing to the increase in prevalence of structural heart diseases.
Aortic valve stenosis indication occupied more than one-third of the total market in 2015.
Adult age group segment is expected to grow at the highest rate of 11.1%.
China occupied one-fifth of the total Asia-Pacific structural heart devices market in 2015.
Asia-Pacific is the fastest growing region in the structural heart devices market, and is expected to continue this trend due to increase in healthcare infrastructural development, specifically in China, India, and other developing economies, and rise in structural heart defects.
Structural heart devices are used to treat heart valves defects as well as acquired valvar abnormalities. The market for structural heart devices is growing at a rapid pace, providing an opportunity for key players to enter this market. For instance, in May 2016, Johnson & Johnson announced that will enter structural heart devices market due to the high growth potential.
The major companies profiled in the report include Medtronic plc; St. Jude Medical, Inc., Braile Biomedica; Medical Technology Est., Boston Scientific Corporation, Micro Interventional Devices, Inc., Edwards Lifesciences Corporation, LivaNova PLC, JenaValve Technology, Inc., and Cryolife, Inc.
- Aetna, Inc.
- Bioventus LLC
- DJO Global, Inc.
- elizur Corporation
- IGEA S.p.A.
- Medtronic plc
- Orchid Medical, Inc.
- Orthofix International N.V.
- Ossatec Benelux B.V.
- Smith & Nephew plc
- Verve Consulting Inc.
- Zimmer Biomet Holdings, Inc.